title: Biological mechanisms of glioma invasion and potential therapeutic targets.
abstract: The current understanding of glioma biology reveals targets for anti-invasive therapy which include manipulations of extracellular matrix and receptors, growth factors and cytokines, proteases, cytoskeletal components, oncogenes and tumor suppressor genes. A better understanding of the complex regulation and the signalling molecules involved in glioma invasion is still needed in order to design new and effective treatment modalities towards invasive tumor cells. Representative and valid in vitro experimental systems and animal models of gliomas are necessary for the characterization of the invasive phenotype and further development of anti-invasive therapy. In the future, it will probably be important to move from comparative genomic modelling through protein characterization based on advanced proteomic techniques to analyse tissue samples, where the aim for gliomas should be to compare invaded and non-invaded tissue. This will hopefully render promising new therapeutic targets for gliomas.
authors.affiliation: Department of Anatomy and Cell Biology, University of Bergen, Norway. berit.tysnes@pki.uib.no
authors.forename: B B
authors.initials: BB
authors.lastname: Tysnes
authors.forename: R
authors.initials: R
authors.lastname: Mahesparan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001254:Astrocytoma / Q000235:genetics / Q000473:pathology / Q000628:therapy; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D015815:Cell Adhesion Molecules / Q000502:physiology; D002465:Cell Movement; D002872:Chromosome Deletion; D002879:Chromosomes, Human, Pair 10 / Q000235:genetics; D003599:Cytoskeleton / Q000187:drug effects / Q000648:ultrastructure; D018450:Disease Progression; D010450:Endopeptidases / Q000502:physiology; D005109:Extracellular Matrix / Q000378:metabolism; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy; D005909:Glioblastoma / Q000235:genetics / Q000473:pathology / Q000628:therapy; D005910:Glioma / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D016023:Integrins / Q000502:physiology; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D009374:Neoplasms, Experimental / Q000473:pathology; D051059:PTEN Phosphohydrolase; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D015815:Cell Adhesion Molecules; D006133:Growth Substances; D016023:Integrins; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D025521:Tumor Suppressor Proteins; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D010450:Endopeptidases; D013930:Thromboxane-A Synthase